|
Clinical Trial of Mifepristone for Bipolar Depression Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Clinical Trial of Mifepristone for Bipolar Depression conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Clinical Trial of Mifepristone for Bipolar Depression Clinical research trials and Clinical Trial of Mifepristone for Bipolar Depression healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Clinical Trial of Mifepristone for Bipolar Depression. Clinical Trial of Mifepristone for Bipolar Depression Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Clinical Trial of Mifepristone for Bipolar Depression clinical trial. Subjects frequently obtain the most expert healthcare possible for their Clinical Trial of Mifepristone for Bipolar Depression condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinical Trial of Mifepristone for Bipolar Depression  Clinical Trial of Mifepristone for Bipolar Depression
Clinical Trial of Mifepristone for Bipolar Depression
For Condition: Bipolar Disorder
Status: Recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: The purpose of this study is to determine the effectiveness of the drug mifepristone in treating patients with bipolar depression who are taking mood stabilizers. This study will also investigate how mifepristone and certain hormones cause changes in mood, thinking, and memory in some patients with bipolar depression. Bipolar depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness. Hypothalamic pituitary axis (HPA) hyperactivity is found in patients with bipolar depression. These patients also have cognitive difficulties and endocrine disturbances that may contribute to such dysfunction. Antiglucocorticoid therapies are novel treatments for mood disorders. Mifepristone, a glucocorticoid receptor antagonist, may have antidepressant and positive cognitive effects in patients with mood disorders. This study will examine the effects of mifepristone in combination with mood stabilizers in patients with severe bipolar depression. Participants with bipolar depression will be admitted to the Clinical Center for 3 to 4 weeks. They will be tapered off all psychiatric medications except Depakote (valproate) and/or lithium. Participants will then begin taking a placebo (an inactive pill) and initiate baseline testing in which they will undergo a magnetic resonance imaging (MRI) scan of the brain. At the end of the baseline studies, participants will be randomly assigned to receive mifepristone or to continue taking a placebo. After 1 week, participants taking mifepristone will be switched to placebo; those taking a placebo will be switched to mifepristone. The crossover treatment will continue for 1 week. Those who respond well to treatment and do not require additional antidepressant medications will remain in the study for up to 16 weeks as outpatients. All others will have further short-term treatment and arrangements will be made for long-term treatment. A comparison group of healthy volunteers will be admitted to the Clinical Center for two overnight stays for various procedures. Volunteers may be asked to return to the clinic for further testing.
Details: Bipolar Depression is a severe illness with high rates of psychiatric comorbidity and increased mortality related to suicide and medical illness. Hypothalamic pituitary axis (HPA) hyperactivity are found in bipolar disorder related to depression and mixed states. Patients with bipolar disorder also have cognitive difficulties and endocrine disturbances and may contribute to such dysfunction. Antiglucorticoid therapies are novel treatments of mood disorder. Preliminary data in psychotic depression suggesting that mifepristone (RU 486), a glucocorticoid receptor antagonist, has antidepressant and salutary cognitive effects in a matter of days. In this study we examine the effects of mifepristone in severe bipolar depression in a parallel, double blind placebo controlled experiment. Bipolar subjects maintained on lithium, valproate, or both after washout of prior antidepressants will have a detailed neuroendocrine assessment. Patients (n=75) will receive eight days of mifepristone versus placebo after which patients are blindly crossed over to the opposite arm. Patients and a group of matched controls (n=35) will be compared with neuroendocrine, cognitive, and neurophysiologic testing to fully characterize their phenotype and explore biomarkers of response. It is hypothesized that stigmata of HPA axis hyperactivity and cognitive impairment will be predictive of response to antiglucocorticoid therapy with mifepristone.
Eligibility:
Study Type: Interventional, Treatment, Safety/Efficacy
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA FOR BIPOLAR PATIENTS: Patients must meet the following inclusion criteria in order to participate in the study: a) Male or female inpatients in need of treatment for severe bipolar depression. b) 18-75 years of age. c) Women of childbearing potential must be using an adequate form of contraception as defined by one of the following: 1) a barrier method and 2) oral contraceptives plus a barrier method (women who are on an OCP will be kept on it others must agree to use only a barrier method). d) DSM-IV diagnosis of bipolar depression I/II, severe, with or without psychotic features. e) A current major depressive episode of at least 6 weeks' duration. f) Score of greater than or equal to 28 on the first 24-item HAM-D at the prestudy visit and at the first baseline phase visit. g) Score of 20 or greater on the HAM-D (24) at the end of the baseline period(s) (i.e., at randomization no more than 20% less than entry enrollment criteria). h) Score of greater than or equal to 4 on the CGI-BP scale at the prestudy and first visit and end of baseline phase. i) Judged to be in good physical health on the basis of medical history, physical examination, and laboratory screening. j) Able to understand procedures and agree to participate in the study by giving written informed consent. k) On lithium and/or valproate for at least 4 weeks (2 levels 1 wk apart). l) However patients not on a mood stabilizer can have this started as an outpatient or inpatient for 4 weeks as discussed above. m) Able to come off of prior drugs and PRN zolpidem and lorazepam by start of baseline. EXCLUSION CRITERIA FOR BIPOLAR PATIENTS: Patients will be excluded from the study if they meet any of the following criteria: a) Women who are pregnant, intending to become pregnant in the next month or breast-feeding. b) Treatment with any of the following therapies within the specified interval prior to baseline: Fluoxetine - 2 weeks; Investigational compounds - 4 weeks; MAOIs - 1 week; Other antidepressants - 1 week. c) Contraindication or history of hypersensitivity to mifepristone as well as cortisol, and CRH. d) Clinically significant organ system disease where mifepristone would be contraindicated or interfere with medical treatment. e) Have evidence of any disorder that represents a contraindication to the use of mifepristone (such as adrenal disease or a condition requiring chronic corticosteroid administration). f) History of Addison's Disease, Cushing's Disease, insulin dependent diabetes, or other uncompensated endocrine conditions. g) Evidence of infection, severe liver, respiratory, or renal disease. h) Have clinically significant cardiovascular disease, e.g., angina, valve disease, arrhythmia, cardiac failure. i) Anemia (hemoglobin less than 10 g/dL or hematocrit less than 30%). j) Have a known clotting defect or are receiving anticoagulants. k) Rapid cycling in the last year (defined as greater than 6 episodes). l) History of porphyries. m) Clinically significant abnormalities in physical exam, ECG, or laboratory assessments. n) History of any disease which, in the investigator's opinion may confound the results of the study or pose an additional risk, including but not limited to, history of organic mental disorder, seizures, or mental retardation. o) Substance dependence that is not in sustained full remission (DSM-IV definition). p) Other principal psychiatric diagnosis judged by the investigator to dominate the clinical presentation. In particular, patients with depressive symptoms more than 2 years in duration should be carefully evaluated to determine whether another psychiatric diagnosis exists which could interfere with efficacy and safety measurements. q) History of nonresponse to greater than four trials of antidepressants for the current episode (not including mood stabilizers) will exclude subjects. INCLUSION CRITERIA FOR NORMAL CONTROLS: a) SCID-NP-no psychiatric diagnosis lifetime. b) Ages 18-75. c) Medically and psychiatrically healthy by history and no disallowed medications for 2 weeks, and agrees to no alcohol use for 1 week baseline period of study. d) No history of mood or anxiety disorder in first-degree relatives. e) Women of childbearing potential must be using adequate form of contraception as defined by one of the following: 1) a barrier method and 2) oral contraceptives plus a barrier method. EXCLUSION CRITERIA FOR NORMAL CONTROLS: a) Known hypersensitivity to CRH, hydrocortisone, metyrapone, or mifepristone. b) Women who are pregnant or breast-feeding. c) Clinically significant organ system disease where mifepristone would be contraindicated or interfere with medical treatment. d) History of prophyrias.
Total Enrollment: 110
Location and Contact Information:
National Institute of Mental Health (NIMH) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 020251; 02-M-0251
Study Start Date: August 7, 2002
Record last reviewed: July 7, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00043654
Other Bipolar Disorder Studies:
1. The Treatment of Children and Adolescents with Treatment-Resistant Depression
2. Clinical Trial of Pramipexole in Bipolar Depression
3. Pilot Study of Levetiracetam (Keppra® (Registered Trademark)) for Bipolar Illness
4. Optimizing Electroconvulsive Therapy for Depression
5. Combination Therapy for the Treatment of Bipolar Disorders
Related Studies:
Other Bipolar Disorder Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Clinical Trial of Mifepristone for Bipolar Depression
|
|
|
|
|
|
|
|
